Fig. 1
Stratification of T-ALL patients with the combination of 5 ectopically expressed genes (5-GEC). A Left panels: bar plots showing the distribution of the number of positive genes of the 5 ectopically expressed genes in all the T-ALL patients from our training cohort (including adults and children) (upper panel), or considering either adult T-ALL patients (middle panel) or children T-ALL patients (lower panel). Prognostic groups were defined according to the number of positive genes as follows: P1 (blue) = none of the 5 genes are activated, P2 (red) = 1 or 2 genes are positive, P3 (black) = 3 to 5 genes are activated. Center and right panels: Kaplan-Meier survival curves comparing overall survival (OS, center panel) and event-free survival (EFS, right panel) between the P1, P2 and P3 groups (as determined above, same color code), in the same three subsets of patients (respectively upper, middle and lower panels). The Cox model and logrank p-values are shown for each plot. P-values obtained from univariate Cox's proportional hazards model reflects how well the number of expressed ectopic genes can explain the survival. Logrank p-value reflects the difference between the survival probabilities in P1, P2 and P3 prognosis groups. B and C 5-GEC positivity associates with shorter survival in adult T-ALL patients training and test cohorts. B Training cohort (n = 54, adult T-ALL samples analyzed by RNA-seq, same as in A middle panels). Left panel: bar plot showing the proportion of patients according to the number of positive 5-GEC genes; Center and right panels: Kaplan-Meier plots showing overall survival (OS, center panel) and event-free survival (EFS, right panel) between 5-GEC negative (none of the 5-GEC are expressed) and positive patients (at least one of the 5-GEC expressed). C Test cohort (n = 32, samples analyzed by RT-qPCR). Left panel: Heatmap showing positive samples for the 5-GEC genes; Center and right panels: Kaplan-Meier plots illustrating overall survival (OS, center panel) and event-free survival (EFS, right panel) between 5-GEC negative and positive patients